TY  - JOUR
A1  - Merz, H.
A1  - Fliedner, A.
A1  - Lehrnbecher, T.
A1  - Sebald, Walter
A1  - Müller-Hermelink, H. K.
A1  - Feller, A. C.
T1  - Cytokine expression in B-cell non-Hodgkin lymphomas
N2  - No abstract available
KW  - Biochemie
Y1  - 1990
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-62539
ER  - 
TY  - JOUR
A1  - Merz, H.
A1  - Fliedner, A.
A1  - Orscheschek, K.
A1  - Binder, T.
A1  - Sebald, Walter
A1  - Müller-Hermelink, H. K.
A1  - Feller, A. C.
T1  - Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth
N2  - No abstract available
KW  - Biochemie
Y1  - 1991
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-62483
ER  - 
TY  - JOUR
A1  - Lehrnbecher, T.
A1  - Poot, M.
A1  - Orscheschek, K.
A1  - Sebald, Walter
A1  - Feller, A. C.
A1  - Merz, H.
T1  - Interleukin 7 as interleukin 9 drives phytohemagglutinin-activated T cells through several cell cycles; no synergism between interleukin 7, interleukin 9 and interleukin 4
N2  - The effects of the interlenkins IL-7 and IL-9 on cell cycle progression were investigated by conventional [3H]thymidine incorporation and by the bivariate BrdU/Hoechst technique. 8oth IL· 7 and IL-9 drive phytohemagglutinin-activated T cells through more than one cell cycle, but IL-7 wasmorepotent on cell cycle progression than IL-9. Neither synergistic nor inhibitory effects were seen between various combinations of the lymphokines IL-7, IL-9 and IL-4 compared to each lymphokine alone. When T cells are activated with phytohemagglutinin for 3 days, all or most IL-4 responsive cells respond to IL-7 as weil, whereas only a part of IL-7 responders are IL-4 responders. In contrast, when T cells are activated with phytohemagglutinin for 7 days, the quantitative data of the cell cycle distribution soggest that the population of IL-7 responders is at least an overlapping, if not a real subset of the population of the IL-4 responders.
KW  - Biochemie
Y1  - 1994
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-62438
ER  - 
TY  - JOUR
A1  - Hartmann, Sylvia
A1  - Plütschow, Annette
A1  - Mottok, Anja
A1  - Bernd, Heinz‐Wolfram
A1  - Feller, Alfred C.
A1  - Ott, German
A1  - Cogliatti, Sergio
A1  - Fend, Falko
A1  - Quintanilla‐Martinez, Leticia
A1  - Stein, Harald
A1  - Klapper, Wolfram
A1  - Möller, Peter
A1  - Rosenwald, Andreas
A1  - Engert, Andreas
A1  - Hansmann, Martin‐Leo
A1  - Eichenauer, Dennis A.
T1  - The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
JF  - American Journal of Hematology
N2  - Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) can present with different histopathological growth patterns. The impact of these histopathological growth patterns on relapse characteristics is unknown. We therefore analyzed paired biopsies obtained at initial diagnosis and relapse from 33 NLPHL patients who had received first‐line treatment within German Hodgkin Study Group (GHSG) trial protocols, and from a second cohort of 41 relapsed NLPHL patients who had been treated outside GHSG studies. Among the 33 GHSG patients, 21 patients presented with a typical growth pattern at initial diagnosis, whereas 12 patients had a variant histology. The histopathological growth patterns at initial diagnosis and at relapse were consistent in 67% of cases. A variant histology at initial diagnosis was associated with a shorter median time to lymphoma recurrence (2.8 vs 5.2 years; P = .0219). A similar tendency towards a shorter median time to lymphoma recurrence was observed for patients presenting with a variant histology at relapse, irrespective of the growth pattern at initial diagnosis. Results obtained from the 41 NLPHL patients who had been treated outside GHSG studies were comparable (median time to lymphoma recurrence for variant histology vs typical growth pattern at initial diagnosis: 1.5 vs 7.0 years). In conclusion, the histopathological growth pattern remains consistent at relapse in the majority of NLPHL cases, and has major impact on the time of relapse.
KW  - Hodgkin lymphoma
KW  - relapse
KW  - growth patterns
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-212594
VL  - 94
IS  - 11
SP  - 1208
EP  - 1213
ER  -